Axatilimab + CAR-T for High-Risk Lymphoma
NCT07638982 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 29
Last updated 2026-06-10
Summary
Axatilimab + CAR-T in High-Risk Lymphoma
Conditions
- Diffuse Large B Cell Lymphoma (DLBCL)
- Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- High-grade B-cell Lymphoma (HGBCL)
- High-Grade B-Cell Lymphoma, Nos
- PMBCL
- Follicular Grade 3 Lymphoma
Interventions
- DRUG
-
Axatilimab
Dose Level -1: 0.1mg/kg Dose Level +1: 0.3mg/kg Dose Level +2: 1mg/kg Dose Level +3: 3mg/kg
Sponsors & Collaborators
-
Northside Hospital, Inc.
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-10-31
- Primary Completion
- 2028-12-31
- Completion
- 2029-12-31
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma
NCT00143871 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells
NCT03628612 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE2
-
GM-CSF With or Without Vaccine Therapy After Combination Chemotherapy and Rituximab as First-Line Therapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00324831 ·Status: SUSPENDED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies
NCT06703892 ·Status: RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
NCT00974792 ·Status: UNKNOWN ·Phase: PHASE2
-
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00301821 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
NCT05283720 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
NCT00392834 ·Status: COMPLETED ·Phase: PHASE2
-
Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma
NCT07588698 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT03704714 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma
NCT00389818 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
NCT01539174 ·Status: WITHDRAWN ·Phase: PHASE2
-
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
NCT00007865 ·Status: COMPLETED ·Phase: PHASE2
-
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
NCT02840110 ·Status: TERMINATED
-
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
NCT04803201 ·Status: RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
NCT00274924 ·Status: COMPLETED ·Phase: PHASE2
-
Safety of MB-CART2019.1 in Lymphoma Patients (MB-CART2019.1 Lymphoma / DALY 1)
NCT03870945 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
NCT03704298 ·Status: TERMINATED ·Phase: PHASE1
-
Axi-cel in CNS Lymphoma
NCT04608487 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
NCT03023878 ·Status: COMPLETED ·Phase: PHASE2
-
S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma
NCT01359592 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma
NCT02348216 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma
NCT04257578 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Glofitamab Combined With CAR-T Therapy in R/R DLBCL
NCT07326371 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2